Human African trypanosomiasis is a parasitic infection caused by protozoa belonging to Trypanosoma brucei subspecies. The clinical evolution of this disease is complex and might be because of the parasite itself, as genetic diversity has been observed in T. brucei ssp. We investigated the relationship between the genetic diversity of trypanosomes and the diversity of clinical patterns in Cô te d'Ivoire. We studied clinical sleeping sickness cases, and genetically analysed the trypanosomes isolated from these patients. An important genetic monomorphism among stocks isolated in Cô te d'Ivoire was observed by using various markers: isoenzymes electrophoresis, random amplified polymorphism DNA and PCR of microsatellite sequences. At the same time, the diversity of clinical patterns and evolutions was confirmed by clinical analysis. The existence of an individual susceptibility to disease (human trypanotolerance) should be taken into account even if our genetic conclusions might be distorted because the isolation success rates were particularly poor. In fact, we observed that the isolation success rate varied significantly depending both on the focus of origin (P ¼ 0.0002) and on the ethnic group (P ¼ 0.0317) of the patient. Further investigations are required in order to study a possible selective impact of the use of the kit for in vitro isolation of trypanosomes as an isolation technique.
Introduction
Human African trypanosomiasis (HAT), or sleeping sickness, is a major public health problem in sub-Saharan Africa. Approximately 60 million people are daily exposed to the risk of infection. It is estimated that there are about 500 000 infected but untreated persons (WHO 1998) . The pathogenic agent is the trypanosome Trypanosoma brucei. Classically, T. brucei is subdivided into three subspecies on the basis of extrinsic criteria: T. b. gambiense is responsible for the chronic form in West and Central Africa, T. b. rhodesiense is the agent of the acute form in East Africa, and T. b. brucei, a parasite of cattle, is supposed to be nonpathogenic to humans.
By definition, HAT evolves in two phases: a haematolymphatic stage (first period), for which there are no specific clinical signs (Jannin et al. 1993; Dumas & Bouteille 1996) , leading to a meningo-encephalitic stage, usually characterized by neurological disorders (second period). In the absence of treatment, the disease is invariably fatal. In T. b. gambiense chronic form, the duration of the first period may be several years: the fluctuating parasitaemia remains low and tends to decrease. The appearance of neurological disorders during Tropical Medicine and International Health volume 7 no 7 pp 610-621 july 2002 the second period is often progressive. In acute HAT caused by T. b. rhodesiense, the haemato-lymphatic stage lasts a few weeks to a few months, passage to the meningoencephalitic stage is brutal and death can occur within a few months of onset of this stage.
A diversity of clinical evolutions has been observed for T. b. gambiense, from some chronic forms to asymptomatic forms (Jamonneau et al. 2000a) . At one extreme, a patient from Togo carried trypanosomes (T. b. gambiense) for 21 years with no clinical signs or neurological disorders (Lapeyssonnie 1960) . At the other extreme, some patients detected in Cô te d'Ivoire presented a clinical evolution characteristic of acute HAT (Truc et al. 1997a) . This clinical diversity does not correspond to the traditional definition of the T. b. gambiense clinical forms of HAT.
Genetic diversity within T. b. gambiense has been demonstrated by several studies using molecular markers (Gibson 1986; Paindavoine et al. 1986; Godfrey et al. 1990; Hide et al. 1990 ), but its influence on the clinical evolution of the HAT remains unproven. We intended to investigate the relationships between the genetic diversity of the parasite and that of the clinical patterns. With this aim, we launched a clinical study on patients diagnosed in Cô te d'Ivoire together with a genetic analysis of the populations of trypanosomes isolated from these patients.
Patients and methods

Study areas and patients
This study was conducted from 1996 to 1999 in two active HAT foci of Cô te d'Ivoire: the western-central part of the country (Daloa, Vavoua, Bouaflé, Sinfra, and Bonon) and the south-east (Aboisso) (Figure 1 ). We included patients detected (parasitological evidence) either actively (during five medical surveys) or passively (patients presenting themselves for treatment). All patients were treated in the three centres specialized in HAT treatment: the Projet de Recherches Cliniques sur les Trypanosomoses in Daloa, and the local health centres in Bouaflé and Aboisso. Patients were told of the objectives and protocol of the study, and only those who gave their consent were included in the study (patients younger than 10 years were not included).
Epidemiological data collection
For each patient, the following data were recorded: sex, age, nationality, ethnic group, geographical origin (south-east or mid-west), HAT focus of provenance (Sinfra, Bonon, Daloa, Bouaflé or Aboisso), occupation, existence of family history of HAT, time and mode of diagnosis (passive or active), and treatment schedule. We distinguished two ethnic grouping groups: natives (including patients born in the study areas) and migrants (including subjects from northern Cô te d'Ivoire, Burkina Faso and Mali).
Clinical assessment before treatment
Objective clinical signs that were looked for were:
• palpation (hepatomegaly, splenomegaly, swollen lateral cervical lymph nodes); • cardiovascular investigation (dysrhythmia, heart murmurs and low blood pressure); • dermatological examination (search for initial lesion of inoculation, trypanids); • assessing possible endocrinological disorders (impotence, facial oedema, amenorrhea, abortion); • neurological examination (alteration of mental state, abnormal reflexes, tone disorders, sensory disorders, coordination disorders).
A questionnaire presented to patients covered subjective clinical signs such as asthenia, anorexia, cachexia, fevers, repeated headache, nausea, pruritus, cutaneous rash, sleep disturbances (alteration of circadian rhythm). Questions about the approximate date of appearance of the initial symptoms and the mode of evolution of the disease were also included. On the basis of clinical signs, patients were classified according to the existence and the importance of the following: infectious or inflammatory syndrome, cardiovascular syndrome, digestive syndrome, dermatological syndrome and neuro-psychiatric syndrome (Table 1) .
Serological and parasitological examinations, and stage determination
Each patient underwent serological and parasitological investigations. For serology, the Card Agglutination Test for Trypanosomiasis (T. b. gambiense) was performed using whole blood and plasma (Magnus et al. 1978) . Trypanosomes were detected using the mini Anion Exchange Centrifugation Technique (Lumsden et al. 1979) and by direct microscopic examination of the lymphatic fluid if lymph nodes were swollen.
For stage determination, the tests used on the cerebrospinal fluid (CSF) were: trypanosome detection by double centrifugation (Cattand et al. 1988) and leukocyte counting using a Nageotte counting chamber. A low leukocyte count (£ 5 cells/ll) combined with absence of trypanosomes in CSF is defined as the first stage of the disease. An elevated leukocyte count (>5 cells/ll), with or without trypanosomes in CSF, forms the basis for secondstage diagnosis (WHO 1998).
Isolation of trypanosomes
The stocks were isolated by using the KIVI (Kit for In vitro Isolation of trypanosomes, Aerts et al. 1992 ) and were then multiplied using semidefined culture medium (Cunningham 1977) according to the protocol described by Truc et al. (1992) . For each stock, two pellets of trypanosomes were obtained by centrifugation and stored in liquid nitrogen. Reference stocks (Tables 2 and 3) had been isolated with the KIVI method during or after 1991, the others having been isolated by rodent inoculation.
Multilocus enzyme electrophoresis
Proteins were extracted from one of the two pellets (Truc et al. 1991 Truc et al. (1991) and Truc and Tibayrenc (1993) , and SOD (EC.1.15.1.1) according to Stevens et al. (1989) .
Random amplified polymorphism DNA
The DNA was extracted from the second pellet according to the protocol described by Oury et al. (1998) . Stocks were characterized by the RAPD technique (random amplified polymorphism DNA, Welsh & McClelland 1990; Williams et al. 1990; Tibayrenc et al. 1993) . Seven primers were used: A2 (5¢-TGCCGAGCTG-3¢), A4 (5¢-AATCGGGCTG-3¢), A7 (5¢-GAAACGGGTG-3¢), A8 (5¢-GTGACGTAGG-3¢), A10 (5¢-GTGATCGCAG-3¢), A11 (5¢-CAATCGCCGT-3¢) and A18 (5¢-AGGTGACCGT-3¢).
Polymorphism of chain reaction of microsatellite DNA sequences 
Analysis procedures
Whenever possible, a comparison of two qualitative variables was performed by means of Pearson chi-square tests. Alternatively, we performed Fisher's exact test. The level of significance retained for the tests was 5%. These (Tables 2 and 3) .
For the PCR/microsatellite DNA, the four primers were specific to T. b. gambiense group 1; thus, only two reference stocks, Jua and Peya (Table 3) , were used. Each band obtained, defined by its molecular weight (in base pairs or bp), corresponds to an allele. For each stock, two bands per primer were revealed (X bp/Y bp).
Results
Patients
A total of 139 patients (harbouring trypanosomes) participated in the study; nine came from Aboisso in the SouthEast, and of the 130 remaining patients from the midwest, 82 Gashumba et al. (1988) . came from Sinfra, 27 from Bonon, 13 from Bouaflé and 8 from Daloa. Sixty-eight per cent of patients were detected passively and 71 actively through five medical surveys. Thirty-nine patients were natives (28%) and 100 migrants (72%). This unequal distribution is traditional in Cô te d'Ivoire as most of the migrants work and live close to the cocoa and coffee plantations, which constitute areas of greater HAT transmission risk. One-hundred and nine patients (78.4%) were farmers and 30 (21.6%) declared a family history of HAT.
Isolation of trypanosomes
Of the 139 KIVIs performed before treatment, only 62 (44%) gave a positive result allowing the in vitro culture and multiplication of procyclics. To isolate a maximum of stocks, another KIVI was inoculated for 46 patients (some of whom had already given positive KIVI in the first round). Only 20 of these 46 KIVI (43%) were positive. In total, 64 stocks (46%) were isolated and cultured for genetic identification. These isolation success rates were particularly poor. Thus, we checked whether some of the host characteristics could have affected the success of isolation. We compared the epidemiological parameters of the human population from whom the stocks were isolated (population 'KIVI positive') with the population from whom the isolation failed (population 'KIVI negative'). The HAT focus of origin and the ethnic group had a significant influence on a positive in vitro isolation (P ¼ 0.0002 and P ¼ 0.0317, respectively). More precisely, the isolation rate ranged from 33.7% in the Sinfra focus to 85.2% in the Bonon one. The isolation rate was particularly poor with the Baoule group, natives of the area (7.7%) and was most elevated for the Senoufo migrant group (66.7%).
Isozyme characterization
Of 64 stocks, 61 were zymodeme 3 (Z3, Truc et al. 1997a) . The three other stocks were zymodeme 38 (Z38, Truc et al. 1997a) . The dendrogram (Figure 2) shows the relationships between these two zymodemes, which differ only by the ME locus: Z3 showed heterozygotes at this locus (three bands), while Z38 was a homozygote (one band). These two zymodemes are genetically closely related (d < 0.1). They both belong to group 1 of T. b. gambiense (Gibson 1986 ). Thus, MLEE results showed very low genetic variability in our sample.
RAPD characterization
Random amplified polymorphism DNA analysis allows a very clear distinction between T. congolense and T. brucei ssp. and a clear individualization of group 1 of T. b. gambiense within T. brucei (Waitumbi & Murphy 1993) . Owing to logistic constraints, only 50 stocks in our study were characterized. They all belonged to T. b. gambiense group 1. These results were concordant with those of MLEE, as a low genetic polymorphism was observed. Of the seven primers used, only one (A2) showed a microvariability with three profiles differing between them by only one band (data not shown). The dendrogram is presented in Figure 3 .
Characterization by PCR/microsatellite DNA Because of logistic constraints, only 16 stocks were characterized by PCR/microsatellite ( 
Clinical study
Forty-four patients were in the first stage of the disease (P1), while 95 were in the second stage (P2). The degree of severity for the five syndromes is given in Table 5 . Syndromes were not significantly linked to one another, and only the neuropsychiatric syndrome was significantly linked to stage of disease (P < 0.0001), indicating a high diversity of clinical symptoms among these patients before treatment.
The time of appearance of symptoms was significantly longer (P ¼ 0.0002) for the patients in P2 than for the patients in P1 (Table 6) . Among the 62 patients feeling unwell for more than 12 months, 50 (81%) were diagnosed in P2. However, of 30 patients whose symptoms appeared within 6 months, 22 (73%) were already in P2. Thus, though the appearance of symptoms for more than 12 months seemed to confirm a diagnosis of second stage, a recent appearance of clinical signs was not necessarily a criterion for a first-phase diagnosis. This result suggests a diversity of clinical evolutions.
Correlation between clinical and genetic diversity
We compared the clinical patterns of the patients 'Z3' with those of the patients 'Z38'. Whatever the clinical variable, there was no significant difference between the Table 3 ). 
Discussion
The isolation rates observed were particularly low compared with previous works where success rates were up to 90% in Cô te d'Ivoire and R.P. Congo (Aerts et al. 1992; Truc et al. 1992 ). This may be because of the quality of KIVI batches. To check this hypothesis, two different batches were used during the whole study but the rates of isolation remained low whatever the batch used. Circulation of particular stocks in HAT foci of Cô te d'Ivoire, which could be difficult to isolate with KIVI, could also explain the low rate of isolation. In fact, we observed that the isolation rate varied significantly depending on the focus of the origin of the patient. As the composition of the human populations were similar between one focus and another, a factor related to the parasite might have an influence on the isolation success. Further investigations are required in order to study a possible selective effect of the use of the KIVI. We also observed that the isolation rate varied significantly according to the ethnic group. Thus, a factor related to the host might also have an influence on the success of in vitro isolation of trypanosomes. According to MacNamara et al. (1995) , the failure or the success of KIVI may depend first on the proportion of short (stumpy) forms and long (slender) forms in the blood of the patient at the moment of KIVI isolation. A high number of stumpy forms in blood increases the success of isolating trypanosomes using KIVI because, as within the tsetse fly, only these stumpy forms are able to be transformed into procyclic forms and multiply. Further investigations are required to study the proportions of stumpy and slender forms in patient's blood when performing KIVI isolation in various foci while taking into account the ethnic origin of patient.
The genetic characterization by MLEE and RAPD revealed a very low genetic polymorphism within the stocks under study. Some genetic homogeneity among T. b. gambiense stocks was already known (Gibson 1986; Paindavoine et al. 1986; Godfrey et al. 1990; Hide et al. 1990 ) but a polymorphism as low as that described by Jamonneau et al. (2000b) using 222 stocks isolated in Cô te d'Ivoire from 1992 to 1999 remains unusual. Moreover, a recent study on the characterization of trypanosome stocks from various geographical origins using PCR/microsatellite also highlighted the absence of genetic variability among nine stocks isolated in Cô te d'Ivoire since 1993 belonging to zymodeme Z3 (Biteau et al. 2000) . In the present work, stocks characterized by PCR/microsatellite analysis were monomorphic for two primers, whereas a microvariability was found when using the two other primers. We can notice that the evaluation of the discriminatory potential of the primers actually used for PCR/microsatellite is still in progress. Some patterns obtained with these primers could be specific to T. b. gambiense group 1 (Biteau et al. 2000; Truc et al. in press) .
Thus, whatever the technique used (MLEE, RAPD, PCR/ microsatellite), a low genetic polymorphism was revealed within the stocks currently isolated in Cô te d'Ivoire. Only Z3 seems to be able to spread within the whole country, confirming previous observations (Jamonneau et al. 2000b) . However, according to the assumption of a selection by KIVI, the isolated stocks might not be representative of the natural populations (KIVI positive stocks could be then genetically different from KIVI negative stocks). This hypothesis confirms the need of studying selectivity in isolation techniques. This could be done by trying to directly identify trypanosomes within the biological fluids of man (blood, CSF and lymph juice) without isolation and culture, and using specific molecular markers. The technique of PCR/microsatellite seems to be a promising tool for this purpose, as two primers used in this study highlighted a microvariability within stocks belonging to the same zymodeme (Z3).
The results of the clinical study indicate a significant diversity of clinical pictures. This is in accordance with a previous longitudinal follow-up of patients refusing the treatment in the Sinfra area between 1996 and 1999, which revealed the existence of a diversity of clinical evolutions (Jamonneau et al. 2000a) . In this latter work various clinical patterns were observed, from the chronic form to an acute form, and self-cure cases were suspected. Whatever the parasitic disease, diversity of clinical evolution can be explained either by the virulence of the parasite or by the host susceptibility to disease. In the particular case of Chagas disease, Andrade et al. (1992) have suggested that the various genotypes described within the species Trypanosoma cruzi (Miles et al. 1981) could be partly responsible for the diversity of clinical evolutions. Evidence of a correlation between genotypes and clinical evolutions was shown through experimental pathology (Laurent et al. 1997) , as well as in humans (Montamat et al. 1996) . For HAT caused by T. b. rhodesiense in the Southeast of Uganda, Smith and Bailey (1997) showed that stocks of the Busoga group were more pathogenic than stocks of the Zambezi group using isoenzymatic characterization. In our study, no correlation between clinical diversity in human and genetic diversity of parasites (observed or not) could be shown.
The role of the host in clinical variability could be considered. The existence of an individual susceptibility to disease has been shown, for example, in malaria (Garcia et al. 1998 ) and leishmaniasis (Mary et al. 1999) . It has been suspected for HAT (Ginoux & Frezil 1981) , being called trypanotolerance. This phenomenon has been described for animal trypanosomiasis (Murray et al. 1990; Authié 1994) . There is no experimental data on individual susceptibility to HAT and its genetic explanation, only indirect evidence (Authié et al. 1991; Garcia et al. 2000; Jamonneau et al. 2000a ). In our study, the individual susceptibility to disease seems to better explain the observed data than the genotype of the infecting T. b. gambiense strains. The hypothesis of an individual susceptibility for HAT and its genetic mechanism must be investigated. The fast evolution of part of the patients to the second stage of the disease, together with the suspected existence of trypanotolerant patients, who do not see a physician and/or refuse treatment because they do not feel sick, is a new useful plea again for early diagnosis and treatment and for regular supervision of HAT foci by National Control Programmes. Epidemiological studies on the animal reservoir of gambiense sleeping sickness. Part III. Characterisation of Trypanozoon stocks by isoenzymes and sensitivity to human serum. 
